BAY 81-8973 safety and efficacy for prophylaxis and treatment of bleeds in previously treated children with severe haemophilia A: results of the LEOPOLD Kids Trial.
(2016) In Haemophilia 22(3). p.354-360- Abstract
- BAY 81-8973, a full-length, unmodified, recombinant factor VIII (FVIII) in development for treatment of haemophilia A, has the same primary amino acid sequence as Bayer's sucrose-formulated recombinant FVIII but is produced with more advanced manufacturing technologies.
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/8504912
- author
- Ljung, Rolf
LU
; Kenet, G ; Mancuso, M E ; Kaleva, V ; Rusen, L ; Tseneklidou-Stoeter, D ; Michaels, L A ; Shah, A ; Hong, W and Maas Enriquez, M
- organization
- publishing date
- 2016
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Haemophilia
- volume
- 22
- issue
- 3
- pages
- 354 - 360
- publisher
- John Wiley & Sons Inc.
- external identifiers
-
- pmid:26663410
- scopus:84949977266
- pmid:26663410
- wos:000379715000030
- ISSN
- 1351-8216
- DOI
- 10.1111/hae.12866
- language
- English
- LU publication?
- yes
- id
- 8a447c6b-758b-4a77-aa6e-d853b29f00b7 (old id 8504912)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/26663410?dopt=Abstract
- date added to LUP
- 2016-04-04 06:55:48
- date last changed
- 2025-03-02 00:43:25
@article{8a447c6b-758b-4a77-aa6e-d853b29f00b7, abstract = {{BAY 81-8973, a full-length, unmodified, recombinant factor VIII (FVIII) in development for treatment of haemophilia A, has the same primary amino acid sequence as Bayer's sucrose-formulated recombinant FVIII but is produced with more advanced manufacturing technologies.}}, author = {{Ljung, Rolf and Kenet, G and Mancuso, M E and Kaleva, V and Rusen, L and Tseneklidou-Stoeter, D and Michaels, L A and Shah, A and Hong, W and Maas Enriquez, M}}, issn = {{1351-8216}}, language = {{eng}}, number = {{3}}, pages = {{354--360}}, publisher = {{John Wiley & Sons Inc.}}, series = {{Haemophilia}}, title = {{BAY 81-8973 safety and efficacy for prophylaxis and treatment of bleeds in previously treated children with severe haemophilia A: results of the LEOPOLD Kids Trial.}}, url = {{http://dx.doi.org/10.1111/hae.12866}}, doi = {{10.1111/hae.12866}}, volume = {{22}}, year = {{2016}}, }